EU Council Adopted Major Pharmaceutical Reform Package
The framework establishes new exclusivity periods for medicines to balance innovation and generic competition.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should the EU prioritize drug research incentives over faster access to lower-cost generic medicines?
The EU Council formally adopted its position on a new pharmaceutical reform package on September 28, 2026. This legislation modifies data and market protection periods for new medicines while creating specific incentives for antibiotic development.
Why it matters
The reform aims to improve patient access to medicines across the EU by streamlining intellectual property regulations. It also introduces targeted economic incentives to boost investment in antibiotics, a sector where traditional commercial returns have historically lagged.
Innovative products can reach a general protection cap of 11 years, with a 12-year maximum when specific clinical conditions are met. Antibiotic developers may earn a transferable exclusivity voucher, provided the drug does not exceed annual gross sales of €490 million.
The players
EU Council
The institution representing the member states' governments that sets the political direction and legislative priorities for the European Union.
The details
Companies launching a new medicine receive eight years of data protection followed by one year of market protection. The framework includes a Bolar exemption, which allows generic manufacturers to conduct preparatory studies and regulatory filings before the original medicine's patent expires. Additionally, standard orphan medicinal products—drugs intended for rare diseases—will receive nine years of market exclusivity.
Timeline
May 2026: EU agreement reached on the Critical Medicines Act.
September 28, 2026: The EU Council formally adopted its position on the pharmaceutical package.
The Tech Race
This legislation follows the strategic framework established by the EU Critical Medicines Act. It extends that regulatory approach to ensure the regional pharmaceutical landscape remains competitive while addressing the specific market failures of antibiotic development.
The reform intends to accelerate the entry of generic alternatives to the market through the Bolar exemption. Patients should expect changes in medication availability and pricing once the regulation is officially published and enters into force.
The takeaway
This reform signals a shift toward balancing rapid innovation with long-term generic accessibility across European markets. Stakeholders should monitor the European Parliament for the final ratification of these rules.
What happens next
The European Parliament must formally adopt the regulation and directive before it enters into force upon publication in the Official Journal.
Further reading
For more context on the evolving regulatory landscape, visit our Biotech section.
Live Poll
Should the EU prioritize drug research incentives over faster access to lower-cost generic medicines?
